• Je něco špatně v tomto záznamu ?

Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI)

GG. Toth, B. De Bruyne, P. Kala, FL. Ribichini, F. Casselman, R. Ramos, Z. Piroth, S. Fournier, C. Van Mieghem, M. Penicka, M. Mates, F. Van Praet, I. Degriek, E. Barbato,

. 2018 ; 11 (4) : 269-273. [pub] 20180719

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012529

Clinical benefit of invasive functionally guided revascularization has been mostly investigated and proven for percutaneous coronary intervention. It has never been prospectively evaluated whether a systematic fractional flow reserve (FFR) assessment is also beneficial in guiding coronary artery bypass graft surgery (CABG). The objective of the GRAft patency after FFR-guided versus angiography-guIded CABG (GRAFFITI) trial was to compare an FFR-guided revascularization strategy to the traditional angiography-guided revascularization strategy for patients undergoing CABG. Patients were enrolled with significantly diseased left anterior descending or left main stem and at least one major coronary artery with angiographically intermediate stenosis (30-90% diameter stenosis) that was assessed by FFR. Thereafter, while the FFR values were kept concealed, cardiac surgeons decided their intended procedural strategy based on the coronary angiography alone. At this point, patients underwent 1:1 randomization to either an FFR-guided or an angiography-guided CABG strategy. In case the patient was randomized to angiography-guided arm, cardiac surgeons kept their intended procedural strategy, i.e., CABG was guided solely on the basis of the coronary angiography. In case the patient was randomized to the FFR-guided arm, FFR values were disclosed to the surgeons who revised the surgical protocol according to the functional significance of each coronary stenosis. The primary endpoint of the trial was the rate of graft occlusion at 12 months, assessed by coronary computed tomography or coronary angiography. The secondary endpoints were (1) length of postoperative hospital stay; (2) changes in surgical strategy depending upon FFR results (in FFR-guided group only); and (3) rate of major adverse cardiac and cerebrovascular events, i.e., composite of death, myocardial infarction, stroke, and any revascularization during the follow-up period. This study is the first prospective randomized trial investigating potential clinical benefits, associated with FFR-guided surgical revascularization. TRIAL REGISTRATION: NCT01810224.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012529
003      
CZ-PrNML
005      
20190412112224.0
007      
ta
008      
190405s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12265-018-9818-9 $2 doi
035    __
$a (PubMed)30027499
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Toth, Gabor G $u Department of Cardiology, University Heart Center Graz, Medical University of Graz, Graz, Austria. Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
245    10
$a Study Design of the Graft Patency After FFR-Guided Versus Angiography-Guided CABG Trial (GRAFFITI) / $c GG. Toth, B. De Bruyne, P. Kala, FL. Ribichini, F. Casselman, R. Ramos, Z. Piroth, S. Fournier, C. Van Mieghem, M. Penicka, M. Mates, F. Van Praet, I. Degriek, E. Barbato,
520    9_
$a Clinical benefit of invasive functionally guided revascularization has been mostly investigated and proven for percutaneous coronary intervention. It has never been prospectively evaluated whether a systematic fractional flow reserve (FFR) assessment is also beneficial in guiding coronary artery bypass graft surgery (CABG). The objective of the GRAft patency after FFR-guided versus angiography-guIded CABG (GRAFFITI) trial was to compare an FFR-guided revascularization strategy to the traditional angiography-guided revascularization strategy for patients undergoing CABG. Patients were enrolled with significantly diseased left anterior descending or left main stem and at least one major coronary artery with angiographically intermediate stenosis (30-90% diameter stenosis) that was assessed by FFR. Thereafter, while the FFR values were kept concealed, cardiac surgeons decided their intended procedural strategy based on the coronary angiography alone. At this point, patients underwent 1:1 randomization to either an FFR-guided or an angiography-guided CABG strategy. In case the patient was randomized to angiography-guided arm, cardiac surgeons kept their intended procedural strategy, i.e., CABG was guided solely on the basis of the coronary angiography. In case the patient was randomized to the FFR-guided arm, FFR values were disclosed to the surgeons who revised the surgical protocol according to the functional significance of each coronary stenosis. The primary endpoint of the trial was the rate of graft occlusion at 12 months, assessed by coronary computed tomography or coronary angiography. The secondary endpoints were (1) length of postoperative hospital stay; (2) changes in surgical strategy depending upon FFR results (in FFR-guided group only); and (3) rate of major adverse cardiac and cerebrovascular events, i.e., composite of death, myocardial infarction, stroke, and any revascularization during the follow-up period. This study is the first prospective randomized trial investigating potential clinical benefits, associated with FFR-guided surgical revascularization. TRIAL REGISTRATION: NCT01810224.
650    12
$a cévní protézy $7 D001807
650    _2
$a koronární angiografie $x metody $7 D017023
650    _2
$a koronární bypass $x metody $7 D001026
650    _2
$a nemoci koronárních tepen $x diagnóza $x patofyziologie $x chirurgie $7 D003324
650    _2
$a koronární cévy $x diagnostické zobrazování $x patofyziologie $x chirurgie $7 D003331
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a frakční průtoková rezerva myokardu $x fyziologie $7 D053805
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a prospektivní studie $7 D011446
650    _2
$a jednoduchá slepá metoda $7 D016037
650    _2
$a chirurgie s pomocí počítače $x metody $7 D025321
650    _2
$a výsledek terapie $7 D016896
650    12
$a průchodnost cév $7 D014654
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a De Bruyne, Bernard $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
700    1_
$a Kala, Petr $u Department of Cardiology and Internal Medicine, University Hospital Brno and Medical Faculty of Masaryk University, Brno, Czech Republic.
700    1_
$a Ribichini, Flavio L $u Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
700    1_
$a Casselman, Filip $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
700    1_
$a Ramos, Ruben $u Hospital Santa Marta - Centro Hospitalar Lisboa Central, Lisbon, Portugal.
700    1_
$a Piroth, Zsolt $u Hungarian Institute of Cardiology, Budapest, Hungary.
700    1_
$a Fournier, Stephane $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
700    1_
$a Van Mieghem, Carlos $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
700    1_
$a Penicka, Martin $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
700    1_
$a Mates, Martin $u Cardiovascular Center, Na Homolce Hospital, Prague, Czech Republic.
700    1_
$a Van Praet, Frank $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
700    1_
$a Degriek, Ivan $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium.
700    1_
$a Barbato, Emanuele $u Cardiovascular Research Center Aalst, OLV Clinic, OLV Hospital, Moorselbaan, 164, B-9300, Aalst, Belgium. emanuele.barbato@olvz-aalst.be. Division of Cardiology, Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy. emanuele.barbato@olvz-aalst.be.
773    0_
$w MED00184059 $t Journal of cardiovascular translational research $x 1937-5395 $g Roč. 11, č. 4 (2018), s. 269-273
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30027499 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190412112242 $b ABA008
999    __
$a ok $b bmc $g 1391839 $s 1050834
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 11 $c 4 $d 269-273 $e 20180719 $i 1937-5395 $m Journal of cardiovascular translational research $n J Cardiovasc Transl Res $x MED00184059
LZP    __
$a Pubmed-20190405
Zpět

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace